NeoStem Announces New Publication That Supports Positive Results of AMR-001 for Treatment of AMI
October 10, 2012 - (Neostem) - "NeoStem, Inc., an emerging leader in the fast growing cell therapy market, announced today that a new article published by the International Scholarly Research Network provides further evidence that AMR-001, NeoStem's lead product candidate through its Amorcyte subsidiary, appears capable of preserving heart muscle functiion following a large myocardial infarction. Amorcyte demonstrated in its Phase 1 trial that AMR-001 preserved heart muscle functiion when a therapeutic dose of cells was administered." Read Full Article
